| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Two Product Concentration Risk | 30.1 | 25.4 | 17.1 | | | | | |
| Other | 58.5 | 47.1 | 31.8 | | | | | |
| Total revenues [+] | 88.6 | 72.5 | 48.9 | 51.2 | 41.4 | 26.8 | 19.9 | 9.7 |
| Licensing | | | | | | | 0.0 | 0.1 |
| Healthcare | | | | | | | 19.9 | 9.7 |
| Other income | | | | | | | | 0.0 |
| Revenue growth [+] | 22.2% | 48.3% | -4.5% | 23.7% | 54.5% | 34.3% | 105.2% | 485.3% |
| Two Product Concentration Risk | 18.7% | 48.3% | | | | | | |
| Cost of goods sold [+] | 25.4 | 18.2 | 14.5 | 16.7 | 16.5 | 13.5 | 9.8 | 5.2 |
| Supplies costs | | | | | | | -9.8 | -5.2 |
| Gross profit | 63.2 | 54.3 | 34.4 | 34.4 | 24.9 | 13.3 | 10.1 | 4.5 |
| Gross margin | 71.3% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% |
| Selling, general and administrative [+] | 58.2 | 41.3 | 31.2 | 33.1 | 29.2 | 25.0 | 25.0 | 19.0 |
| Sales and marketing | | | | | | | 7.4 | 6.5 |
| General and administrative | | | | | | | 17.6 | 12.5 |
| Research and development | 3.1 | 11.1 | 2.4 | 2.1 | 0.8 | 0.4 | 0.7 | 0.3 |
| Equity in earnings | -11.1 | -5.3 | 4.7 | | | | | |
| Other operating expenses | -1.9 | -1.6 | -1.7 | | 0.4 | | | |
| EBITDA [+] | -5.5 | -1.8 | 7.5 | 1.2 | -4.0 | -10.8 | -14.5 | -14.2 |
| EBITDA growth | 212.0% | -123.3% | 542.9% | -129.3% | -62.8% | -25.9% | 2.2% | 41.2% |
| EBITDA margin | -6.2% | -2.4% | 15.4% | 2.3% | -9.7% | -40.2% | -72.8% | -146.3% |
| Depreciation | 1.5 | 1.6 | 1.9 | 1.7 | 1.4 | 1.0 | 0.7 | 0.3 |
| EBITA | -7.0 | -3.3 | 5.7 | -0.6 | -5.4 | -11.8 | -15.2 | -14.5 |
| EBITA margin | -7.8% | -4.6% | 11.6% | -1.1% | -13.0% | -44.1% | -76.4% | -148.9% |
| Amortization of intangibles | 1.6 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.4 | 0.4 |
| EBIT [+] | -8.5 | -3.5 | 5.5 | -0.8 | -5.6 | -12.2 | -15.6 | -14.8 |
| EBIT growth | 145.7% | -163.2% | -820.1% | -86.4% | -53.9% | -21.9% | 5.1% | 46.1% |
| EBIT margin | -9.6% | -4.8% | 11.2% | -1.5% | -13.6% | -45.4% | -78.1% | -152.6% |
| Non-recurring items [+] | 0.7 | 0.2 | 0.4 | 4.0 | -0.4 | | 0.3 | |
| Asset impairment | | 0.2 | 0.4 | 4.0 | | | 0.3 | |
| Loss (gain) on sale of assets | 0.7 | | | | -0.4 | | | |
| Interest expense | 7.2 | 5.4 | 2.2 | 2.5 | 2.7 | 3.0 | 2.8 | 1.1 |
| Interest expense | 7.2 | 5.4 | 2.2 | 2.5 | 2.7 | 3.0 | 2.8 | 1.1 |
| Other income (expense), net [+] | 2.4 | -8.7 | -6.3 | 7.2 | 22.6 | 2.3 | -0.5 | 0.0 |
| Gain (loss) on sale of assets | | | | | | -0.4 | | |
| Gain (loss) on investments | -2.9 | -10.1 | | | | | | |
| Other | 0.1 | 0.2 | -0.1 | 0.6 | 0.1 | -0.9 | 1.5 | -1.1 |
| Pre-tax income | -14.0 | -17.9 | -3.4 | -0.1 | 14.6 | -12.9 | -19.2 | -15.9 |
| Income taxes | 0.1 | 0.1 | 0.0 | -0.3 | 0.0 | -0.9 | -0.1 | 0.0 |
| Tax rate | | | | 234.4% | 0.0% | 7.2% | 0.6% | 0.0% |
| Minority interest | | | -0.1 | -0.3 | | | | |
| Net income | -14.1 | -18.5 | -3.4 | 0.2 | 14.6 | -12.0 | -19.1 | -15.9 |
| Net margin | -15.9% | -25.5% | -6.9% | 0.3% | 35.3% | -44.8% | -95.7% | -163.6% |
| |
| Basic EPS [+] | ($0.51) | ($0.69) | ($0.13) | $0.01 | $0.67 | ($0.60) | ($1.50) | ($1.66) |
| Growth | -25.7% | 432.7% | -2054.1% | -99.0% | -211.5% | -60.0% | -9.8% | 49.9% |
| Diluted EPS [+] | ($0.51) | ($0.69) | ($0.13) | $0.01 | $0.61 | ($0.60) | ($1.50) | ($1.66) |
| Growth | -25.7% | 432.7% | -2142.3% | -99.0% | -202.6% | -60.0% | -9.8% | 49.9% |
| |
| Shares outstanding (basic) [+] | 27.5 | 26.8 | 25.9 | 25.3 | 21.9 | 20.0 | 12.7 | 9.6 |
| Growth | 2.6% | 3.3% | 2.3% | 15.5% | 9.4% | 57.2% | 33.1% | 4.9% |
| Shares outstanding (diluted) [+] | 27.5 | 26.8 | 25.9 | 26.5 | 23.8 | 20.0 | 12.7 | 9.6 |
| Growth | 2.6% | 3.3% | -2.2% | 11.1% | 18.9% | 57.2% | 33.1% | 4.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |